Risk Stratification for Bladder Tumor Recurrence, Stage and Grade by Urinary Nuclear Matrix Protein 22 and Cytology
- 1 March 2004
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 45 (3) , 304-313
- https://doi.org/10.1016/j.eururo.2003.10.020
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analysesUrology, 2003
- EXCLUSION CRITERIA ENHANCE THE SPECIFICITY AND POSITIVE PREDICTIVE VALUE OF NMP22* AND BTA STAT [dagger]Journal of Urology, 1999
- Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladderDiagnostic Cytopathology, 1999
- Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuriaInternational Journal of Urology, 1999
- Evaluation of Urinary Level of NMP22 as a Diagnostic Marker for Stage pTa-pT1 Bladder Cancer: Comparison with Urinary Cytology and BTA TestEuropean Urology, 1999
- Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancerUrology, 1998
- CAN URINE BOUND DIAGNOSTIC TESTS REPLACE CYSTOSCOPY IN THE MANAGEMENT OF BLADDER CANCER?Journal of Urology, 1998
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996
- NuMA is required for the proper completion of mitosis.The Journal of cell biology, 1993
- Identification of a nuclear protein matrixBiochemical and Biophysical Research Communications, 1974